Industry
Biotechnology
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Loading...
Open
3.98
Mkt cap
2.3B
Volume
11M
High
4.00
P/E Ratio
-12.06
52-wk high
5.34
Low
3.75
Div yield
N/A
52-wk low
1.64
Portfolio Pulse from
November 21, 2024 | 8:15 pm
Portfolio Pulse from
November 07, 2024 | 6:15 pm
Portfolio Pulse from
November 07, 2024 | 4:30 pm
Portfolio Pulse from
November 07, 2024 | 2:30 pm
Portfolio Pulse from
November 07, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 2:19 pm
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 12:50 pm
Portfolio Pulse from Avi Kapoor
September 03, 2024 | 5:41 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.